Curie Institute is an interdisciplinary, non-profit foundation dedicated to cancer research and treatment. It was founded by Marie Curie and her family, with the aim of applying the progress of science to human health. It is recognized as one of Europe’s best places for interdisciplinary research and translational medicine. It is at the heart of the Montagne Ste Genevieve Campus, comprising the highest density of high excellence interdisciplinary research and education in France. It strongly promotes interactions between fundamental research and medicine, and is a European leader in this field. It is strongly involved in the development of innovative technologies for medicine, and has an active IP protection and exploitation policy. Importantly, Curie Institute involves an hospital dedicated to cancer treatment, with 350 beds, around 10000 patients treated per year.
MMBM team is part of CNRS Curie Department UMR168, ~140 persons, the largest laboratory in France entirely dedicated to research at the interface between Physics, Chemistry, and Biology. It is a multidisciplinary team of about 25 persons, dedicated to the development of innovative tools for biology and medicine using research in physics and chemistry. It has published more than 100 scientific papers, and issued more than 10 patents in the field of microfluidics, several of which are commercially exploited, and/or licenced to leading companies in the field. It has been at the origin of the startup FLUIGENT, one of the leading European companies in Microfluidics, partner of this project. The team has been coordinating 3 EU projects, and participating to a total of 12. It is also cofounder of the new Pierre Gilles de Gennes Institute for Microfludics (see “significant infrastructures” below), which was just awarded a prestigious “LABEX” grant, and will provide a unique environment for the project.